Deutsche Bank Ag\ Rocket Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 44,468 shares of RCKT stock, worth $627,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,468

Previous 39,671 12.09%

Holding current value

$627,443

Previous $854,000 3.86%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$17.6 - $25.88 $84,427 - $124,146	4,797 Added 12.09%	44,468 $821,000
Q2 2024 Aug 14, 2024	SELL	$20.66 - $26.72 $57,083 - $73,827	-2,763 Reduced 6.51%	39,671 $854,000
Q1 2024 May 15, 2024	BUY	$26.16 - $30.74 $9,286 - $10,912	355 Added 0.84%	42,434 $1.14 Million
Q4 2023 Feb 14, 2024	BUY	$16.78 - $31.94 $98,716 - $187,903	5,883 Added 16.25%	42,079 $1.26 Million
Q3 2023 Nov 09, 2023	SELL	$15.07 - $24.05 $4,249 - $6,782	-282 Reduced 0.77%	36,196 $741,000
Q2 2023 Aug 14, 2023	SELL	$16.59 - $23.6 $299,333 - $425,814	-18,043 Reduced 33.09%	36,478 $724,000
Q1 2023 May 15, 2023	BUY	$15.79 - $22.6 $176,958 - $253,278	11,207 Added 25.87%	54,521 $933,000
Q4 2022 Feb 13, 2023	SELL	$15.5 - $22.76 $36,037 - $52,917	-2,325 Reduced 5.09%	43,314 $847,000
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $186,700 - $277,862	15,093 Added 49.41%	45,639 $728,000
Q2 2022 Aug 11, 2022	SELL	$7.96 - $16.64 $90,154 - $188,464	-11,326 Reduced 27.05%	30,546 $420,000
Q1 2022 May 13, 2022	BUY	$13.16 - $23.68 $101,121 - $181,957	7,684 Added 22.48%	41,872 $664,000
Q4 2021 Feb 11, 2022	BUY	$21.52 - $36.02 $82,593 - $138,244	3,838 Added 12.65%	34,188 $747,000
Q3 2021 Nov 04, 2021	SELL	$27.42 - $48.97 $35,399 - $63,220	-1,291 Reduced 4.08%	30,350 $907,000
Q2 2021 Aug 11, 2021	SELL	$39.41 - $47.25 $1.73 Million - $2.07 Million	-43,792 Reduced 58.05%	31,641 $1.4 Million
Q1 2021 May 13, 2021	BUY	$43.34 - $65.91 $1.99 Million - $3.03 Million	45,975 Added 156.07%	75,433 $3.35 Million
Q4 2020 Feb 16, 2021	SELL	$23.3 - $59.57 $5.77 Million - $14.8 Million	-247,838 Reduced 89.38%	29,458 $1.62 Million
Q3 2020 Nov 12, 2020	BUY	$20.5 - $28.59 $5.02 Million - $7 Million	244,942 Added 757.07%	277,296 $6.34 Million
Q2 2020 Aug 13, 2020	SELL	$13.32 - $22.61 $6.55 Million - $11.1 Million	-491,830 Reduced 93.83%	32,354 $676,000
Q1 2020 May 14, 2020	BUY	$9.71 - $25.11 $2.52 Million - $6.52 Million	259,637 Added 98.14%	524,184 $7.31 Million
Q4 2019 Feb 14, 2020	BUY	$11.07 - $24.23 $2.76 Million - $6.05 Million	249,769 Added 1690.14%	264,547 $6.02 Million
Q3 2019 Nov 14, 2019	SELL	$10.85 - $14.78 $123,321 - $167,989	-11,366 Reduced 43.47%	14,778 $170,000
Q2 2019 Aug 14, 2019	SELL	$15.0 - $19.81 $170,055 - $224,585	-11,337 Reduced 30.25%	26,144 $391,000
Q1 2019 May 15, 2019	SELL	$13.45 - $19.01 $290,103 - $410,026	-21,569 Reduced 36.53%	37,481 $656,000
Q4 2018 Feb 14, 2019	SELL	$11.21 - $23.53 $1.58 Million - $3.31 Million	-140,597 Reduced 70.42%	59,050 $874,000
Q3 2018 Dec 21, 2021	BUY	$18.5 - $25.49 $2.88 Million - $3.97 Million	155,595 Added 353.21%	199,647 $4.92 Million
Q3 2018 Nov 14, 2018	SELL	$18.5 - $25.49 $8.57 Million - $11.8 Million	-463,116 Reduced 91.31%	44,052 $1.08 Million
Q2 2018 Apr 21, 2020	BUY	$14.58 - $23.0 $6 Million - $9.47 Million	411,802 Added 431.81%	507,168 $9.96 Million
Q2 2018 Aug 14, 2018	BUY	$14.58 - $23.0 $1.33 Million - $2.1 Million	91,255 Added 2219.78%	95,366 $1.87 Million
Q1 2018 Oct 18, 2019	BUY	$11.68 - $19.19 $25,988 - $42,697	2,225 Added 117.97%	4,111 $76,000
Q1 2018 May 15, 2018	BUY	$11.68 - $19.19 $22,028 - $36,192	1,886 New	1,886 $35,000

Others Institutions Holding RCKT

# of Institutions

209

Shares Held

93.2M

Call Options Held

319K

Put Options Held

70.3K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $1.07B
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account